About Cardiovascular Systems (NASDAQ:CSII)
Cardiovascular Systems, Inc., a medical technology company, develops, manufactures, and markets devices to treat vascular diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 4 French 1.25 Peripheral OAS, Diamondback 360 1.50 Peripheral OAS, Diamondback 360 2.00 Peripheral OAS, and Stealth 360 Peripheral OAS, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries. The company sells its products directly to hospitals or office-based labs. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:CSII
CUSIP14161910
Phone651-259-1600
Debt
Debt-to-Equity Ratio0.17%
Current Ratio4.65%
Quick Ratio4.13%
Price-To-Earnings
Trailing P/E Ratio750.67
Forward P/E Ratio-321.71
P/E GrowthN/A
Sales & Book Value
Annual Sales$204.91 million
Price / Sales3.65
Cash Flow$0.1550 per share
Price / Cash145.28
Book Value$3.62 per share
Price / Book6.22
Profitability
EPS (Most Recent Fiscal Year)$0.03
Net Income$-1,790,000.00
Net Margins-1.62%
Return on Equity-0.50%
Return on Assets-0.31%
Miscellaneous
Employees579
Outstanding Shares33,220,000
Cardiovascular Systems (NASDAQ:CSII) Frequently Asked Questions
What is Cardiovascular Systems' stock symbol?
Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."
How were Cardiovascular Systems' earnings last quarter?
Cardiovascular Systems, Inc. (NASDAQ:CSII) released its earnings results on Wednesday, February, 7th. The medical device company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.03. The medical device company earned $52.63 million during the quarter, compared to analyst estimates of $53.39 million. Cardiovascular Systems had a negative net margin of 1.62% and a negative return on equity of 0.50%. The business's quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.03 earnings per share. View Cardiovascular Systems' Earnings History.
When is Cardiovascular Systems' next earnings date?
What guidance has Cardiovascular Systems issued on next quarter's earnings?
Cardiovascular Systems issued an update on its third quarter earnings guidance on Wednesday, February, 7th. The company provided EPS guidance of ($0.03)-$0.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.03. The company issued revenue guidance of $55-56.5 million, compared to the consensus revenue estimate of $58.69 million.
What price target have analysts set for CSII?
6 Wall Street analysts have issued 1-year price objectives for Cardiovascular Systems' stock. Their forecasts range from $23.00 to $30.00. On average, they expect Cardiovascular Systems' share price to reach $26.50 in the next twelve months. View Analyst Ratings for Cardiovascular Systems.
What are Wall Street analysts saying about Cardiovascular Systems stock?
Here are some recent quotes from research analysts about Cardiovascular Systems stock:
- 1. According to Zacks Investment Research, "Cardiovascular Systems exited second-quarter fiscal 2018 on a solid note with year-over-year increase in revenues at both CAD and PAD businesses. Also, the expansion is gross margin was impressive. Moreover, the company is putting efforts in product innovation through R&D investments. The market is also looking forward to the recently-launched coronary device in Japan, reflecting the company’s focus on international expansion. On the flip side, Cardiovascular Systems faces cutthroat competition in the niche space. Coming to profitability, Cardio Vascular incurred net loss in the recently-reported second quarter. In fact, the company has a long history of net losses since inception. Also, the lowered revenue guidance for fiscal 2018 is discouraging. Over the past year, Cardiovascular Systems has been trading below the broader industry." (2/12/2018)
- 2. Needham & Company LLC analysts commented, "CSII’s F1Q18 revenue and EPS beat consensus though we note that CSII had announced on 9/18/17 that it expected to miss its original guidance due to the hurricanes. F2Q18 revenue and EPS guidance were below consensus although management maintained its FY18 revenue guidance since it expects recent sales force changes to reaccelerate its coronary sales. While CSII faces its most difficult comp in F2Q18, we expect growth to accelerate in CY18 as comps begin to ease, the sales force changes improve coronary sales, CSII launches its coronary product in Japan and support products (such as guide wires) in the US." (10/26/2017)
Who are some of Cardiovascular Systems' key competitors?
Some companies that are related to Cardiovascular Systems include Irhythm Technologies (IRTC), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), OraSure Technologies (OSUR), Glaukos (GKOS), Luminex (LMNX), K2M Group (KTWO), MiMedx Group (MDXG), LeMaitre Vascular (LMAT), CryoLife (CRY), AtriCure (ATRC), AngioDynamics (ANGO), Cerus (CERS), Anika Therapeutics (ANIK), Tactile Systems Technology (TCMD), SurModics (SRDX) and Accuray (ARAY).
Who are Cardiovascular Systems' key executives?
Cardiovascular Systems' management team includes the folowing people:
- Mr. Scott Raymond Ward MS, B.Sc., Chairman, Chief Exec. Officer and Pres (Age 58)
- Mr. Laurence L. Betterley, VP of Admin. (Age 64)
- Ms. Laura J. Gillund, Chief Talent Officer (Age 57)
- Mr. Jeffrey S. Points, Chief Financial Officer
- Ms. Rhonda J. Robb, Chief Operating Officer
Has Cardiovascular Systems been receiving favorable news coverage?
Media headlines about CSII stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cardiovascular Systems earned a news sentiment score of 0.19 on Accern's scale. They also gave news stories about the medical device company an impact score of 46.43 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Cardiovascular Systems' major shareholders?
Cardiovascular Systems' stock is owned by a number of of retail and institutional investors. Top institutional investors include
CHAMPLAIN INVESTMENT PARTNERS, LLC
(6.81%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Camber Capital Management Llc, Edward M Brown, Kevin J Kenny, Laura Gillund, Laurence L Betterley, Paul A Koehn and Scott R Ward. View Institutional Ownership Trends for Cardiovascular Systems.
How do I buy shares of Cardiovascular Systems?
Shares of CSII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cardiovascular Systems' stock price today?
One share of CSII stock can currently be purchased for approximately $22.52.
How big of a company is Cardiovascular Systems?
Cardiovascular Systems has a market capitalization of $753.72 million and generates $204.91 million in revenue each year. The medical device company earns $-1,790,000.00 in net income (profit) each year or $0.03 on an earnings per share basis. Cardiovascular Systems employs 579 workers across the globe.
How can I contact Cardiovascular Systems?
Cardiovascular Systems' mailing address is 1225 OLD HWY 8 NW, ST. PAUL MN, 55112. The medical device company can be reached via phone at 651-259-1600 or via email at [email protected]
MarketBeat Community Rating for Cardiovascular Systems (CSII)
MarketBeat's community ratings are surveys of what our community members think about Cardiovascular Systems and other stocks. Vote "Outperform" if you believe CSII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CSII will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cardiovascular Systems (NASDAQ:CSII) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Cardiovascular Systems in the last 12 months. Their average twelve-month price target is $26.50, suggesting that the stock has a possible upside of 17.67%. The high price target for CSII is $30.00 and the low price target for CSII is $23.00. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Buy |
| Consensus Rating Score: | 2.00 | 2.00 | 2.00 | 2.57 |
| Ratings Breakdown: | 1 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s) |
| Consensus Price Target: | $26.50 | $26.50 | $31.50 | $34.25 |
| Price Target Upside: | 17.67% upside | 13.98% upside | 31.69% upside | 20.22% upside |
Cardiovascular Systems (NASDAQ:CSII) Consensus Price Target History
Cardiovascular Systems (NASDAQ:CSII) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Cardiovascular Systems (NASDAQ:CSII) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Cardiovascular Systems (NASDAQ CSII) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.30%
Institutional Ownership Percentage: 82.56%
Cardiovascular Systems (NASDAQ CSII) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/31/2017 | Edward M Brown | Director | Sell | 20,000 | $29.16 | $583,200.00 | |  |
| 8/30/2017 | Edward M Brown | Director | Sell | 13,031 | $29.09 | $379,071.79 | | |
| 8/17/2017 | Laura Gillund | Insider | Sell | 2,350 | $30.42 | $71,487.00 | 88,633 | |
| 8/17/2017 | Scott R Ward | CEO | Sell | 5,529 | $30.41 | $168,136.89 | 282,536 | |
| 8/16/2017 | Alexander Rosenstein | General Counsel | Sell | 979 | $30.71 | $30,065.09 | 52,296 | |
| 8/16/2017 | Kevin J Kenny | COO | Sell | 4,733 | $30.74 | $145,492.42 | 153,339 | |
| 8/16/2017 | Laurence L Betterley | CFO | Sell | 4,443 | $30.74 | $136,577.82 | 223,557 | |
| 5/17/2017 | Alexander Rosenstein | General Counsel | Sell | 219 | $32.30 | $7,073.70 | 34,265 | |
| 11/18/2016 | Alexander Rosenstein | General Counsel | Sell | 529 | $26.80 | $14,177.20 | 34,484 | |
| 11/18/2016 | Edward M Brown | Director | Sell | 10,000 | $26.78 | $267,800.00 | | |
| 11/18/2016 | Laura Gillund | Insider | Sell | 1,268 | $26.79 | $33,969.72 | 69,541 | |
| 11/15/2016 | Edward M Brown | Director | Sell | 10,000 | $24.95 | $249,500.00 | | |
| 10/10/2016 | Paul A Koehn | SVP | Sell | 30,910 | $25.07 | $774,913.70 | 110,200 | |
| 9/20/2016 | Camber Capital Management Llc | Major Shareholder | Sell | 1,100,000 | $23.26 | $25,586,000.00 | | |
| 9/7/2016 | Paul A Koehn | SVP | Sell | 5,969 | $25.02 | $149,344.38 | 73,321 | |
| 8/22/2016 | Alexander Rosenstein | General Counsel | Sell | 234 | $23.82 | $5,573.88 | 38,035 | |
| 8/22/2016 | Kevin J Kenny | COO | Sell | 3,166 | $23.95 | $75,825.70 | 168,231 | |
| 8/22/2016 | Laura Gillund | Insider | Sell | 1,395 | $23.93 | $33,382.35 | 82,817 | |
| 8/22/2016 | Laurence L Betterley | CFO | Sell | 3,568 | $23.96 | $85,489.28 | 253,031 | |
| 8/22/2016 | Paul A Koehn | SVP | Sell | 2,527 | $23.92 | $60,445.84 | 100,125 | |
| 8/17/2016 | Paul A Koehn | SVP | Sell | 4,000 | $22.17 | $88,680.00 | 102,652 | |
| 2/26/2016 | Paul A Koehn | SVP | Sell | 956 | $38.79 | $37,083.24 | 73,266 | |
| 2/23/2016 | Camber Capital Management Llc | Major Shareholder | Buy | 250,000 | $7.55 | $1,887,500.00 | | |
| 1/25/2016 | Scott R Ward | CEO | Buy | 2,700 | $9.30 | $25,110.00 | 9,533 | |
| 10/2/2015 | Robert J. Thatcher | insider | Sell | 64,700 | $16.31 | $1,055,257.00 | 126,978 | |
| 9/2/2015 | David Martin | CEO | Sell | 19,646 | $23.81 | $467,771.26 | 458,818 | |
| 9/1/2015 | Kevin J Kenny | COO | Sell | 5,289 | $23.85 | $126,142.65 | 105,330 | |
| 9/1/2015 | Laurence L Betterley | CFO | Sell | 9,597 | $23.96 | $229,944.12 | 191,414 | |
| 9/1/2015 | Paul A Koehn | SVP | Sell | 4,946 | $23.86 | $118,011.56 | 73,738 | |
| 9/1/2015 | Robert J Thatcher | Insider | Sell | 5,282 | $23.85 | $125,975.70 | 126,978 | |
| 8/18/2015 | David Martin | CEO | Sell | 17,688 | $23.99 | $424,335.12 | | |
| 8/18/2015 | Kevin J. Kenny | COO | Sell | 3,913 | $24.00 | $93,912.00 | 117,458 | |
| 8/18/2015 | Laurence L Betterley | CFO | Sell | 8,476 | $24.00 | $203,424.00 | | |
| 8/18/2015 | Paul A. Koehn | SVP | Sell | 4,402 | $23.99 | $105,603.98 | 84,439 | |
| 8/18/2015 | Robert J. Thatcher | insider | Sell | 2,960 | $23.99 | $71,010.40 | 138,243 | |
| 8/12/2015 | Brent G Blackey | Director | Buy | 2,500 | $22.74 | $56,850.00 | | |
| 5/28/2015 | Paul A Koehn | SVP | Sell | 4,389 | $27.86 | $122,277.54 | | |
| 5/1/2015 | Brent G Blackey | Director | Buy | 2,500 | $29.38 | $73,450.00 | | |
| 2/10/2015 | David Martin | CEO | Sell | 7,500 | $35.85 | $268,875.00 | | |
| 2/5/2015 | David Martin | CEO | Sell | 4,500 | $34.96 | $157,320.00 | | |
| 1/29/2015 | Kevin J Kenny | VP | Sell | 4,212 | $35.00 | $147,420.00 | | |
| 9/3/2014 | David Martin | CEO | Sell | 10,248 | $28.85 | $295,654.80 | | |
| 9/3/2014 | Kevin J Kenny | VP | Sell | 3,528 | $28.85 | $101,782.80 | | |
| 9/3/2014 | Laurence L Betterley | CFO | Sell | 4,674 | $28.82 | $134,704.68 | | |
| 9/3/2014 | Paul A Koehn | SVP | Sell | 2,612 | $28.85 | $75,356.20 | | |
| 9/3/2014 | Robert J Thatcher | Insider | Sell | 2,791 | $28.85 | $80,520.35 | | |
| 8/28/2014 | Paul A Koehn | SVP | Sell | 1,315 | $28.82 | $37,898.30 | | |
| 8/22/2014 | David Martin | CEO | Sell | 13,957 | $29.03 | $405,171.71 | | |
| 8/22/2014 | Kevin J Kenny | VP | Sell | 2,914 | $29.09 | $84,768.26 | | |
| 8/22/2014 | Laurence L Betterley | CFO | Sell | 6,578 | $29.02 | $190,893.56 | | |
| 8/22/2014 | Paul A Koehn | SVP | Sell | 2,755 | $29.06 | $80,060.30 | | |
| 8/22/2014 | Robert J Thatcher | Insider | Sell | 3,225 | $29.06 | $93,718.50 | | |
| 8/19/2014 | David Martin | CEO | Sell | 11,754 | $29.28 | $344,157.12 | | |
| 8/19/2014 | Kevin J Kenny | VP | Sell | 2,117 | $29.28 | $61,985.76 | | |
| 8/19/2014 | Laurence L Betterley | CFO | Sell | 5,725 | $29.28 | $167,628.00 | | |
| 8/19/2014 | Paul A Koehn | SVP | Sell | 2,168 | $29.28 | $63,479.04 | | |
| 8/19/2014 | Robert J Thatcher | Insider | Sell | 2,537 | $29.28 | $74,283.36 | | |
| 7/16/2014 | David Martin | CEO | Sell | 10,703 | $28.83 | $308,567.49 | | |
| 7/16/2014 | Kevin J Kenny | VP | Sell | 3,007 | $28.83 | $86,691.81 | | |
| 7/16/2014 | Laurence L Betterley | CFO | Sell | 3,984 | $28.83 | $114,858.72 | | |
| 7/16/2014 | Paul A Koehn | SVP | Sell | 2,716 | $28.83 | $78,302.28 | | |
| 7/16/2014 | Robert J Thatcher | Insider | Sell | 2,939 | $28.83 | $84,731.37 | | |
| 4/25/2014 | Kevin Kenny | VP | Sell | 15,484 | $28.79 | $445,784.36 | 66,841 | |
| 2/24/2014 | David Martin | CEO | Sell | 29,200 | $37.31 | $1,089,452.00 | 354,052 | |
| 2/20/2014 | Kevin Kenny | VP | Sell | 6,779 | $36.02 | $244,179.58 | 82,325 | |
| 1/30/2014 | David Martin | CEO | Sell | 50,000 | $35.12 | $1,756,000.00 | 354,052 | |
| 1/30/2014 | Robert Thatcher | VP | Sell | 35,139 | $35.06 | $1,231,973.34 | 84,014 | |
| 11/22/2013 | Robert Thatcher | VP | Sell | 22,384 | $32.82 | $734,642.88 | 84,014 | |
| 10/31/2013 | James E Flaherty | Insider | Sell | 34,819 | $30.35 | $1,056,756.65 | | |
| 10/23/2013 | David Martin | CEO | Sell | 154,080 | $27.73 | $4,272,638.40 | | |
| 10/23/2013 | James E Flaherty | Insider | Sell | 36,682 | $26.85 | $984,911.70 | | |
| 10/23/2013 | Robert J Thatcher | VP | Sell | 23,426 | $28.19 | $660,378.94 | | |
| 10/22/2013 | Kevin J Kenny | VP | Sell | 5,608 | $27.31 | $153,154.48 | | |
| 10/16/2013 | Kevin J Kenny | VP | Sell | 4,182 | $22.95 | $95,976.90 | | |
| 10/14/2013 | David Martin | CEO | Sell | 21,170 | $22.00 | $465,740.00 | 354,052 | |
| 9/20/2013 | David Martin | CEO | Sell | 6,702 | $20.24 | $135,648.48 | 354,052 | |
| 9/20/2013 | James Flaherty | Insider | Sell | 2,066 | $20.28 | $41,898.48 | 140,736 | |
| 9/20/2013 | Robert Thatcher | VP | Sell | 1,274 | $20.28 | $25,836.72 | 130,105 | |
| 9/19/2013 | Laurence Betterley | CFO | Sell | 2,694 | $20.32 | $54,742.08 | 203,362 | |
| 9/19/2013 | Paul Koehn | SVP | Sell | 1,094 | $20.32 | $22,230.08 | 59,074 | |
| 9/18/2013 | David Martin | CEO | Sell | 8,030 | $20.94 | $168,148.20 | 360,754 | |
| 9/18/2013 | James Flaherty | Insider | Sell | 2,970 | $20.94 | $62,191.80 | 142,802 | |
| 9/18/2013 | Laurence Betterley | CFO | Sell | 4,324 | $20.93 | $90,501.32 | 206,056 | |
| 9/18/2013 | Paul Koehn | SVP | Sell | 1,732 | $20.93 | $36,250.76 | 60,168 | |
| 9/18/2013 | Robert Thatcher | VP | Sell | 1,731 | $20.94 | $36,247.14 | 131,379 | |
| 9/10/2013 | John Friedman | Director | Sell | 48,273 | $20.73 | $1,000,699.29 | 8,000 | |
| 8/30/2013 | David Martin | CEO | Sell | 21,552 | $20.64 | $444,833.28 | 297,649 | |
| 8/30/2013 | James Flaherty | Insider | Sell | 7,165 | $20.64 | $147,885.60 | 122,329 | |
| 8/30/2013 | Kevin Kenny | VP | Sell | 1,899 | $20.64 | $39,195.36 | 87,780 | |
| 8/30/2013 | Laurence Betterley | CFO | Sell | 8,692 | $20.64 | $179,402.88 | 177,554 | |
| 8/27/2013 | David Martin | CEO | Sell | 27,229 | $21.07 | $573,715.03 | 319,201 | |
| 8/27/2013 | James Flaherty | Insider | Sell | 9,051 | $21.07 | $190,704.57 | 129,494 | |
| 8/27/2013 | Kevin Kenny | VP | Sell | 2,396 | $21.07 | $50,483.72 | 89,679 | |
| 8/27/2013 | Laurence Betterley | CFO | Sell | 10,982 | $21.07 | $231,390.74 | 186,246 | |
| 8/16/2013 | James Flaherty | Insider | Sell | 1,255 | $20.51 | $25,740.05 | 138,545 | |
| 8/16/2013 | Laurence Betterley | CFO | Sell | 1,568 | $20.51 | $32,159.68 | 197,228 | |
| 8/14/2013 | James Flaherty | Insider | Sell | 4,902 | $21.31 | $104,461.62 | 139,800 | |
| 8/13/2013 | Kevin Kenny | VP | Sell | 2,529 | $21.20 | $53,614.80 | 92,723 | |
| 8/8/2013 | James Flaherty | Insider | Sell | 19,649 | $22.27 | $437,583.23 | 120,282 | |
| 7/30/2013 | David Martin | CEO | Sell | 11,094 | $19.69 | $218,440.86 | | |
| 7/30/2013 | Laurence L Betterley | CFO | Sell | 6,579 | $19.72 | $129,737.88 | | |
| 7/30/2013 | Robert J Thatcher | VP | Sell | 3,112 | $19.86 | $61,804.32 | | |
| 6/3/2013 | James E Flaherty | Insider | Sell | 10,000 | $21.00 | $210,000.00 | | |
| 5/31/2013 | Paul A Koehn | VP | Sell | 2,472 | $20.00 | $49,440.00 | | |
| 5/28/2013 | Kevin J Kenny | VP | Sell | 4,182 | $19.95 | $83,430.90 | | |
| 5/20/2013 | Glen D Nelson | Director | Buy | 10,250 | $18.47 | $189,317.50 | | |
| 5/16/2013 | Glen D Nelson | Director | Buy | 4,753 | $18.93 | $89,974.29 | | |
| 5/13/2013 | Glen D Nelson | Director | Buy | 18,393 | $18.11 | $333,097.23 | | |
| 11/13/2012 | Glen D Nelson | Director | Buy | 33,000 | $11.96 | $394,680.00 | | |
| 8/23/2012 | David Martin | CEO | Sell | 10,510 | $9.07 | $95,325.70 | | |
| 8/23/2012 | James E Flaherty | Insider | Sell | 4,018 | $9.07 | $36,443.26 | | |
| 8/23/2012 | Laurence L Betterley | CFO | Sell | 4,770 | $9.07 | $43,263.90 | | |
| 8/23/2012 | Paul A Koehn | VP | Sell | 2,496 | $9.07 | $22,638.72 | | |
(Data available from 1/1/2013 forward)
Cardiovascular Systems (NASDAQ CSII) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Cardiovascular Systems (CSII) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 17 at 11:07 AM |
| Cardiovascular Systems, Inc. (CSII) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 15 at 3:25 AM |
| Cardiovascular Systems (CSII) Lowered to "Sell" at BidaskClub
www.americanbankingnews.com - April 14 at 6:22 PM |
 | Cardiovascular Systems, Inc. to Webcast Fiscal 2018 Third-Quarter Earnings Conference Call Wednesday, May 2
finance.yahoo.com - April 11 at 4:38 PM |
| Cardiovascular Systems (CSII) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - April 9 at 6:03 AM |
| Cardiovascular Systems, Inc. (CSII) Expected to Post Quarterly Sales of $55.63 Million
www.americanbankingnews.com - April 7 at 2:47 AM |
| -$0.02 Earnings Per Share Expected for Cardiovascular Systems, Inc. (CSII) This Quarter
www.americanbankingnews.com - April 5 at 3:18 PM |
| Cardiovascular Systems (CSII) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 3 at 11:00 AM |
| Cardiovascular Systems (CSII) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - March 30 at 6:14 PM |
| Cardiovascular Systems (CSII) Lowered to "Strong Sell" at BidaskClub
www.americanbankingnews.com - March 29 at 6:54 PM |
| Cardiovascular Systems (CSII) Upgraded to Sell by BidaskClub
www.americanbankingnews.com - March 27 at 4:00 PM |
| Cardiovascular Systems (CSII) Downgraded by ValuEngine
www.americanbankingnews.com - March 25 at 7:32 PM |
| Cardiovascular Systems (CSII) vs. Owens & Minor (OMI) Head to Head Comparison
www.americanbankingnews.com - March 25 at 3:22 PM |
| Cardiovascular Systems, Inc. (CSII) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - March 21 at 3:28 AM |
| Zacks: Analysts Expect Cardiovascular Systems, Inc. (CSII) to Post -$0.02 Earnings Per Share
www.americanbankingnews.com - March 19 at 3:14 PM |
| Cardiovascular Systems (CSII) and Invacare (IVC) Critical Comparison
www.americanbankingnews.com - March 16 at 12:31 PM |
 | Cardiovascular Systems (CSII) Presents At Barclays Global Healthcare Conference 2018 - Slideshow
seekingalpha.com - March 14 at 10:12 AM |
| Cardiovascular Systems Inc (CSII) Sees Large Increase in Short Interest
www.americanbankingnews.com - March 13 at 1:53 AM |
| BidaskClub Upgrades Cardiovascular Systems (CSII) to "Buy"
www.americanbankingnews.com - March 10 at 6:34 PM |
| Cardiovascular Systems (CSII) Up 2% Since Earnings Report: Can It Continue?
finance.yahoo.com - March 9 at 5:41 PM |
| Cardiovascular Systems Presents LIBERTY 360° 18-Month Outcomes at CRT18 Interventional Cardiology Conference
finance.yahoo.com - March 6 at 4:57 PM |
| Cardiovascular Systems Inc (CSII) Expected to Post Quarterly Sales of $55.63 Million
www.americanbankingnews.com - March 4 at 4:50 AM |
| -$0.02 Earnings Per Share Expected for Cardiovascular Systems Inc (CSII) This Quarter
www.americanbankingnews.com - March 2 at 7:12 PM |
| Champlain Investment Partners LLC Purchases 396,145 Shares of Cardiovascular Systems Inc (CSII)
www.americanbankingnews.com - February 27 at 5:40 AM |
| Cortina Asset Management LLC Sells 98,118 Shares of Cardiovascular Systems Inc (CSII)
www.americanbankingnews.com - February 26 at 3:04 PM |
| Cardiovascular Systems Inc (CSII) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - February 24 at 3:40 AM |
| Cardiovascular Systems (CSII) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 15 at 4:43 PM |
| Cardiovascular Systems, Inc. Announces First Patients Treated from Radial Access Using Its Diamondback 360® Extended Length Peripheral Orbital Atherectomy Device
finance.yahoo.com - February 14 at 9:17 AM |
| -$0.02 EPS Expected for Cardiovascular Systems Inc (CSII) This Quarter
www.americanbankingnews.com - February 13 at 7:14 PM |
| Cardiovascular Systems (CSII) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - February 12 at 4:52 PM |
| Equities Analysts Set Expectations for Cardiovascular Systems Inc's Q3 2018 Earnings (CSII)
www.americanbankingnews.com - February 12 at 4:44 AM |
| Cardiovascular Systems Inc to Post Q3 2018 Earnings of ($0.01) Per Share, Northcoast Research Forecasts (CSII)
www.americanbankingnews.com - February 12 at 4:44 AM |
| Q3 2018 EPS Estimates for Cardiovascular Systems Inc (CSII) Cut by Leerink Swann
www.americanbankingnews.com - February 12 at 4:44 AM |
| Cardiovascular Systems (CSII) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - February 9 at 9:30 PM |
| Brokers Set Expectations for Cardiovascular Systems Inc's Q4 2019 Earnings (CSII)
www.americanbankingnews.com - February 9 at 5:50 PM |
| Q4 2018 Earnings Forecast for Cardiovascular Systems Inc Issued By Leerink Swann (CSII)
www.americanbankingnews.com - February 9 at 3:52 PM |
| Cardiovascular Systems (CSII) Price Target Lowered to $30.00 at Leerink Swann
www.americanbankingnews.com - February 8 at 1:30 PM |
| Cardiovascular Systems (CSII) Announces Quarterly Earnings Results
www.americanbankingnews.com - February 8 at 9:56 AM |
| Where Cardiovascular Systems Inc (NASDAQ:CSII) Stands In Terms Of Earnings Growth Against Its Industry
finance.yahoo.com - February 8 at 8:48 AM |
| Cardiovascular Systems, Inc. Reports Fiscal 2018 Second-Quarter Financial Results
finance.yahoo.com - February 8 at 8:48 AM |
| Cardiovascular Systems reports 2Q loss
finance.yahoo.com - February 8 at 8:48 AM |
| Cardiovascular Systems, Inc. Appoints Jeff Points as Chief Financial Officer
finance.yahoo.com - February 8 at 8:48 AM |
| Cardiovascular Systems (CSII) Updates Q3 Earnings Guidance
www.americanbankingnews.com - February 8 at 12:12 AM |
 | Cardiovascular Systems' Micro Crown Now Available in Japan
www.zacks.com - February 6 at 9:15 AM |
| Cardiovascular Systems' Micro Crown Now Available in Japan
finance.yahoo.com - February 5 at 4:16 PM |
| Cardiovascular Systems (CSII) Cut to Sell at BidaskClub
www.americanbankingnews.com - February 3 at 8:46 PM |
| Financial Survey: Cryolife (CRY) & Cardiovascular Systems (CSII)
www.americanbankingnews.com - February 3 at 7:20 PM |
| Cardiovascular Systems, Inc. Announces Commercial Launch in Japan
finance.yahoo.com - February 1 at 4:18 PM |
| Cardiovascular Systems (CSII) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - January 31 at 3:38 AM |
| Cardiovascular Systems Inc (CSII) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - January 30 at 3:28 AM |
Cardiovascular Systems (NASDAQ:CSII) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cardiovascular Systems (NASDAQ:CSII) Income Statement, Balance Sheet and Cash Flow Statement
Cardiovascular Systems (NASDAQ CSII) Stock Chart for Saturday, April, 21, 2018
Loading chart…
